Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: Effects of nebivolol and valsartan alone and in combination

Journal of the American Society of Hypertension

Volumn 9, Issue 7, 2015, Pages 526-535

  Izzo, Joseph L ^a   Khan, Safi U ^a   Saleem, Osman ^a   Osmond, Peter J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin receptor blockers; Beta blockers; Central blood pressure; Clinical trial; Myocardial oxygen consumption; Nebivolol; Pulse wave analysis; Rate pressure product; Valsartan

Indexed keywords

NEBIVOLOL; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ADULT; AFRICAN AMERICAN; AMBULATORY 24 HOUR CARDIAC OXYGEN CONSUMPTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MONOTHERAPY; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; CARDIAC MUSCLE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEART RATE; METABOLISM; OXYGEN CONSUMPTION; RANDOMIZATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIUM; NEBIVOLOL; OXYGEN CONSUMPTION; RANDOM ALLOCATION; VALSARTAN;

EID: 84942980427     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2015.03.009     Document Type: Conference Paper

References (32)

1. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens 2010;4: 90-8.
2. Izzo JL Jr, Rajpal M, Karan S, Srikakarlapudi S, Osmond P. Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. J Am Soc Hypertens 2012;6:117-23.
3. Izzo JL Jr. Brachial vs. central systolic pressure and pulse wave transmission indicators: a critical analysis. Am J Hypertens 2014;27:1433-42.
4. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.
5. Kostis JB, Sedjro JE, Cabrera J, et al. Visit-to-visit blood pressure variability and cardiovascular death in the Systolic Hypertension in the Elderly Program. J Clin Hypertens 2014;16:34-40.
6. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-80.
7. Izzo JL Jr, Weintraub HS, Duprez DA, et al. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results. J Clin Hypertens 2011;13: 722-30.
8. Izzo JL, Zion AS. Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues. Ther Adv Cardiovasc Dis 2011;5:169-78.
9. Luzardo L, Lujambio I, Sottolano M, et al. 24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study. Hypertens Res 2012;35:980-7.
10. Weiss W, Gohlisch C, Harsch-Gladisch C, Tolle M, Zidek W, van der Giet M. Oscillometric estimation of central blood pressure: validation of the Mobil-OGraph in comparison with the SphygmoCor device. Blood Press Monit 2012;17:128-31.
11. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23.
12. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
13. Izzo JL Jr, Yedlapati SH, Faheem SM, Younus U, Osmond PJ. Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril. J Am Soc Hypertens 2012;6:399-404.
14. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005;26:2259-68.
15. Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002;162:2313-21.
16. Levy RL, White PD, Stroud WD, Hillman CC. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA1945;129:585-8.
17. Benetos A, Thomas F, Bean K, Albaladejo P, Palatini P, Guize L. Resting heart rate in older people: a predictor of survival to age 85. J Am Geriatr Soc 2003;51:284-5.
18. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure). J Am Coll Cardiol 2009;53:2150-8.
19. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-35.
20. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
22. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
23. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288:1491-8.
24. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
25. Jaques H. NICE guideline on hypertension. Eur Heart J 2013;34:406-8.
26. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014;30:485-501.
27. Hansen TW, Thijs L, Li Y, et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension 2010;55:1049-57
28. [Erratum appears in Hypertension. 2010 Jun;55(6):e27].
29. Asayama K, Kikuya M, Schutte R, et al. Home blood pressure variability as cardiovascular risk factor in the population of Ohasama. Hypertension 2013;61:61-9.
30. Gao S, Hendrie HC, Wang C, et al. Redefined blood pressure variability measure and its association with mortality in elderly primary care patients. Hypertension 2014;64:45-52.
31. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13.
32. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366: 895-906.